Annexon Announces Pricing of $125 Million Underwritten Public Offering

Core Viewpoint - Annexon, Inc. has announced a public offering of 13,001,120 shares of common stock priced at $6.25 per share, along with prefunded warrants for 7,000,000 shares at a price of $6.249 per share, aiming to raise approximately $125 million in gross proceeds [1][2]. Group 1: Offering Details - The total gross proceeds from the offering are expected to be $125 million before deducting underwriting discounts and commissions [2]. - The offering is set to close on June 7, 2024, pending customary closing conditions [2]. - Annexon has granted underwriters a 30-day option to purchase an additional 3,000,168 shares of common stock [2]. Group 2: Company Background - Annexon is a biopharmaceutical company focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases affecting the body, brain, and eye [5]. - The company's approach targets upstream C1q to inhibit the classical complement inflammatory cascade, with therapeutic candidates showing promise in conditions like Guillain-Barré syndrome, Huntington's disease, and geographic atrophy [5]. Group 3: Regulatory Information - The shares are being offered under a shelf registration statement on Form S-3, which was filed and declared effective by the SEC on April 1, 2024 [3]. - The offering is conducted through a prospectus supplement and accompanying prospectus, which can be accessed via the SEC's website [3].